Full Press Release Details
Results of Annual General Meeting
The Annual General Meeting of PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( PureTech Health or the Company ) was held at 11 a.m. EDT/4
p.m. BST on Wednesday, June 15, 2022.
All of the resolutions proposed at the Annual General Meeting were duly passed by the shareholders on a poll.
The results of the poll, incorporating the proxy votes lodged in advance of the meeting, are set out below.
| Resolutions | For | % | Against | % | Withheld | Total votes cast | ||||||||||||||||||
| 001. To approve the Company s Annual Report and Accounts for year ended 31 December 2021 | 216,387,000 | 100.00 | 0 | 0.00 | 529,458 | 216,387,000 | ||||||||||||||||||
| 002. To approve the Directors Remuneration Report | 186,654,636 | 86.20 | 29,871,462 | 13.80 | 390,360 | 216,526,098 | ||||||||||||||||||
| 003. To elect Ms. Sharon Barber-Lui as a director | 216,911,434 | 100.00 | 2,288 | 0.00 | 2,736 | 216,913,722 | ||||||||||||||||||
| 004. To elect Dr. Raju Kucherlapati as a director | 214,260,532 | 98.78 | 2,653,190 | 1.22 | 2,736 | 216,913,722 | ||||||||||||||||||
| 005. To elect Dr. John LaMattina as a director | 208,222,704 | 95.99 | 8,691,018 | 4.01 | 2,736 | 216,913,722 | ||||||||||||||||||
| 006. To elect Ms. Kiran Mazumdar-Shaw as a director | 186,900,260 | 86.16 | 30,013,462 | 13.84 | 2,736 | 216,913,722 | ||||||||||||||||||
| 007. To elect Dame Marjorie Scardino as a director | 216,877,331 | 99.98 | 37,071 | 0.02 | 2,056 | 216,914,402 | ||||||||||||||||||
| 008. To elect Mr. Christopher Viehbacher as a director | 190,417,512 | 87.78 | 26,496,210 | 12.22 | 2,736 | 216,913,722 | ||||||||||||||||||
| 009. To elect Dr. Robert Langer as a director | 212,747,748 | 98.08 | 4,165,974 | 1.92 | 2,736 | 216,913,722 | ||||||||||||||||||
| 010. To elect Ms. Daphne Zohar as a director | 216,905,622 | 100.00 | 8,100 | 0.00 | 2,736 | 216,913,722 | ||||||||||||||||||
| 011. To elect Dr. Bharatt Chowrira as a director | 216,706,444 | 99.90 | 207,278 | 0.10 | 2,736 | 216,913,722 | ||||||||||||||||||
| 012. To reappoint KPMG LLP as Auditors of the Company | 212,180,052 | 97.82 | 4,729,435 | 2.18 | 6,971 | 216,909,487 | ||||||||||||||||||
| 013. To authorize the Audit Committee to determine the Auditors remuneration | 212,703,757 | 98.06 | 4,211,701 | 1.94 | 1,000 | 216,915,458 |
| 014. To authorize the allotment of shares | 212,364,212 | 97.90 | 4,551,246 | 2.10 | 1,000 | 216,915,458 | ||||||||||||||||||
| 015. To disapply pre-emption rights | 216,589,860 | 99.85 | 324,482 | 0.15 | 2,116 | 216,914,342 | ||||||||||||||||||
| 016. To further disapply pre-emption rights for acquisitions and specified capital investments. | 204,225,243 | 94.15 | 12,689,099 | 5.85 | 2,116 | 216,914,342 | ||||||||||||||||||
| 017. To authorize market purchase of own shares | 216,386,703 | 99.76 | 528,755 | 0.24 | 1,000 | 216,915,458 | ||||||||||||||||||
| 018. To authorize general meetings to be called on not less than 14 clear days notice | 212,326,728 | 97.88 | 4,588,730 | 2.12 | 1,000 | 216,915,458 |
About PureTech Health
PureTech is a clinical-stage
biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and
gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of
scientists, clinicians and industry leaders.
This pipeline, which is being advanced both internally and through PureTech s Founded Entities, is
comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech s most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points
based on unique insights in immunology and drug development.
For more information, visit www.puretechhealth.com or connect with us on
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to our future prospects, developments and strategies.
The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current
expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption Risk Factors in our Annual Report on Form 20-F for the year ended
December 31, 2021 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate
in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.